AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] NeoGenomics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

NeoGenomics disclosed that director Elizabeth Floegel resigned from the Company’s Board, effective immediately. The filing expressly states her resignation did not result from any disagreement with the Company on its operations, policies or practices. The notice is a straightforward governance update recorded under Item 5.02 and does not include any additional information about reasons beyond the statement or any immediate replacement for the Board seat.

This disclosure informs investors of a change in board composition while explicitly denying any dispute with management; the filing contains no financial data, operational changes or other material transactions.

NeoGenomics ha comunicato che la consigliera Elizabeth Floegel si è dimessa dal Consiglio con effetto immediato. Il deposito indica espressamente che le dimissioni non sono dovute a divergenze con la Società riguardo alle sue attività, politiche o prassi. L'avviso è un aggiornamento di governance registrato ai sensi dell'Item 5.02 e non fornisce ulteriori dettagli sui motivi né indica un sostituto immediato per il posto in Consiglio.

Questa comunicazione informa gli azionisti di una modifica nella composizione del Consiglio, negando esplicitamente qualsiasi conflitto con la direzione; il deposito non contiene dati finanziari, cambiamenti operativi o altre operazioni rilevanti.

NeoGenomics informó que la directora Elizabeth Floegel renunció al Consejo con efecto inmediato. La presentación declara expresamente que su renuncia no se debe a ningún desacuerdo con la Compañía respecto a sus operaciones, políticas o prácticas. El aviso es una actualización de gobernanza registrada bajo el Item 5.02 y no incluye información adicional sobre los motivos ni un reemplazo inmediato para el puesto en el Consejo.

Esta divulgación informa a los inversores sobre un cambio en la composición del consejo, negando explícitamente cualquier disputa con la dirección; la presentación no contiene datos financieros, cambios operativos ni otras transacciones materiales.

NeoGenomicsëŠ� ì´ì‚¬ Elizabeth Floegelì� 즉시 효력으로 ì´ì‚¬íšŒì—ì„� 사임했다ê³� 공시했습니다. 제출 서류ëŠ� 그녀ì� 사임ì� 회사ì� ìš´ì˜, ì •ì±… ë˜ëŠ” 관행과ì� ì–´ë– í•� 불ì¼ì¹˜ë¡œ ì¸í•œ ê²ƒì´ ì•„ë‹˜ì� 명시ì ìœ¼ë¡� ë°ížˆê³� 있습니다. 해당 통지ëŠ� Item 5.02ì—� 따른 단순í•� 거버넌스 ì—…ë°ì´íЏë¡�, 진술 ì™¸ì— ì¶”ê°€ 사유ë‚� ì´ì‚¬íš� ìžë¦¬ì� 즉ê°ì ì¸ 후임ì—� 대í•� ì •ë³´ë¥� í¬í•¨í•˜ì§€ 않습니다.

ì� 공시ëŠ� ê²½ì˜ì§„ê³¼ì� ë¶„ìŸì� 명시ì ìœ¼ë¡� ë¶€ì¸í•˜ë©´ì„œ ì´ì‚¬íš� 구성ì� ë³€ë™ì„ 투ìžìžì—ê²� 알리ëŠ� ë‚´ìš©ì´ë©°, 제출 서류ì—는 재무 ì •ë³´, ìš´ì˜ ë³€ê²� ë˜ëŠ” 기타 중요 거래가 í¬í•¨ë˜ì–´ 있지 않습니다.

NeoGenomics a annoncé que l'administratrice Elizabeth Floegel a démissionné du conseil d'administration avec effet immédiat. Le dépôt précise expressément que sa démission n'est pas due à un désaccord avec la Société concernant ses opérations, ses politiques ou ses pratiques. L'avis constitue une simple mise à jour de gouvernance enregistrée sous l'Item 5.02 et ne fournit pas d'informations supplémentaires sur les motifs ni de remplaçant immédiat pour le siège au conseil.

Cette divulgation informe les investisseurs d'un changement dans la composition du conseil tout en niant explicitement tout litige avec la direction ; le dépôt ne contient pas de données financières, de modifications opérationnelles ni d'autres transactions matérielles.

NeoGenomics gab bekannt, dass Direktorin Elizabeth Floegel mit sofortiger Wirkung aus dem Vorstand zurückgetreten ist. Die Einreichung stellt ausdrücklich fest, dass ihr Rücktritt nicht auf Meinungsverschiedenheiten mit dem Unternehmen über dessen Geschäftstätigkeit, Richtlinien oder Praktiken zurückzuführen ist. Die Mitteilung ist ein einfacher Governance-Update, das unter Item 5.02 erfasst wurde, und enthält keine weiteren Angaben zu den Gründen oder einen unmittelbaren Ersatz für den Vorstandssitz.

Diese Offenlegung informiert Investoren über eine Änderung in der Zusammensetzung des Vorstands und weist ausdrücklich jeden Konflikt mit dem Management zurück; die Einreichung enthält keine finanziellen Daten, betrieblichen Änderungen oder sonstige wesentliche Transaktionen.

Positive
  • Transparent disclosure of the director resignation and explicit statement that the departure was not due to any disagreement with the company
  • Timely compliance with Item 5.02 reporting requirements, ensuring investors are informed of board changes
Negative
  • Board vacancy created by the immediate resignation with no successor named in the filing
  • Limited detail on reasons for departure beyond the denial of disagreement, leaving uncertainty about long-term governance implications

Insights

TL;DR: A single director resigned effective immediately; the company states there was no disagreement—limited governance concern absent further detail.

The filing records a voluntary resignation by Elizabeth Floegel from the Board with an explicit statement that the departure was not due to any disagreement with the Company on operations, policies or practices. The company did not disclose a successor or additional context. From a governance perspective, timely disclosure of the resignation and the denial of any disagreement reduce the likelihood of immediate market concern, but the absence of a replacement schedule leaves a short-term vacancy in board composition.

TL;DR: Director departure disclosed with no dispute; filing contains no financial or operational impact—therefore appears immaterial to near-term financials.

The Item 5.02 disclosure is concise: a director resigned and the company affirmed the resignation was not related to any disagreement. The report contains no earnings, transaction or liability information tied to the resignation. For investors focused on financial performance, there is no new metric or transaction to reassess. Material impact would require additional information, such as replacement plans or related strategic shifts, which the filing does not provide.

NeoGenomics ha comunicato che la consigliera Elizabeth Floegel si è dimessa dal Consiglio con effetto immediato. Il deposito indica espressamente che le dimissioni non sono dovute a divergenze con la Società riguardo alle sue attività, politiche o prassi. L'avviso è un aggiornamento di governance registrato ai sensi dell'Item 5.02 e non fornisce ulteriori dettagli sui motivi né indica un sostituto immediato per il posto in Consiglio.

Questa comunicazione informa gli azionisti di una modifica nella composizione del Consiglio, negando esplicitamente qualsiasi conflitto con la direzione; il deposito non contiene dati finanziari, cambiamenti operativi o altre operazioni rilevanti.

NeoGenomics informó que la directora Elizabeth Floegel renunció al Consejo con efecto inmediato. La presentación declara expresamente que su renuncia no se debe a ningún desacuerdo con la Compañía respecto a sus operaciones, políticas o prácticas. El aviso es una actualización de gobernanza registrada bajo el Item 5.02 y no incluye información adicional sobre los motivos ni un reemplazo inmediato para el puesto en el Consejo.

Esta divulgación informa a los inversores sobre un cambio en la composición del consejo, negando explícitamente cualquier disputa con la dirección; la presentación no contiene datos financieros, cambios operativos ni otras transacciones materiales.

NeoGenomicsëŠ� ì´ì‚¬ Elizabeth Floegelì� 즉시 효력으로 ì´ì‚¬íšŒì—ì„� 사임했다ê³� 공시했습니다. 제출 서류ëŠ� 그녀ì� 사임ì� 회사ì� ìš´ì˜, ì •ì±… ë˜ëŠ” 관행과ì� ì–´ë– í•� 불ì¼ì¹˜ë¡œ ì¸í•œ ê²ƒì´ ì•„ë‹˜ì� 명시ì ìœ¼ë¡� ë°ížˆê³� 있습니다. 해당 통지ëŠ� Item 5.02ì—� 따른 단순í•� 거버넌스 ì—…ë°ì´íЏë¡�, 진술 ì™¸ì— ì¶”ê°€ 사유ë‚� ì´ì‚¬íš� ìžë¦¬ì� 즉ê°ì ì¸ 후임ì—� 대í•� ì •ë³´ë¥� í¬í•¨í•˜ì§€ 않습니다.

ì� 공시ëŠ� ê²½ì˜ì§„ê³¼ì� ë¶„ìŸì� 명시ì ìœ¼ë¡� ë¶€ì¸í•˜ë©´ì„œ ì´ì‚¬íš� 구성ì� ë³€ë™ì„ 투ìžìžì—ê²� 알리ëŠ� ë‚´ìš©ì´ë©°, 제출 서류ì—는 재무 ì •ë³´, ìš´ì˜ ë³€ê²� ë˜ëŠ” 기타 중요 거래가 í¬í•¨ë˜ì–´ 있지 않습니다.

NeoGenomics a annoncé que l'administratrice Elizabeth Floegel a démissionné du conseil d'administration avec effet immédiat. Le dépôt précise expressément que sa démission n'est pas due à un désaccord avec la Société concernant ses opérations, ses politiques ou ses pratiques. L'avis constitue une simple mise à jour de gouvernance enregistrée sous l'Item 5.02 et ne fournit pas d'informations supplémentaires sur les motifs ni de remplaçant immédiat pour le siège au conseil.

Cette divulgation informe les investisseurs d'un changement dans la composition du conseil tout en niant explicitement tout litige avec la direction ; le dépôt ne contient pas de données financières, de modifications opérationnelles ni d'autres transactions matérielles.

NeoGenomics gab bekannt, dass Direktorin Elizabeth Floegel mit sofortiger Wirkung aus dem Vorstand zurückgetreten ist. Die Einreichung stellt ausdrücklich fest, dass ihr Rücktritt nicht auf Meinungsverschiedenheiten mit dem Unternehmen über dessen Geschäftstätigkeit, Richtlinien oder Praktiken zurückzuführen ist. Die Mitteilung ist ein einfacher Governance-Update, das unter Item 5.02 erfasst wurde, und enthält keine weiteren Angaben zu den Gründen oder einen unmittelbaren Ersatz für den Vorstandssitz.

Diese Offenlegung informiert Investoren über eine Änderung in der Zusammensetzung des Vorstands und weist ausdrücklich jeden Konflikt mit dem Management zurück; die Einreichung enthält keine finanziellen Daten, betrieblichen Änderungen oder sonstige wesentliche Transaktionen.

0001077183FALSE00010771832025-08-052025-08-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549 
 
FORM 8-K  
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
August 5, 2025
 
NEOGENOMICS, INC.
(Exact name of registrant as specified in its charter) 
 
Nevada
001-35756
74-2897368
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

 
9490 NeoGenomics Way,Fort Myers,Florida33912
(Address of principal executive offices)(Zip Code)
(239) 768-0600
(Registrant’s telephone number, including area code) 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:Trading Symbol(s):Name of each exchange on which registered:
Common Stock, par value $0.001 per shareNEOThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 



Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Board of Director Resignation
On August 5, 2025, Elizabeth Floegel provided NeoGenomics, Inc., a Nevada corporation (the “Company”), with notice of her resignation from the Board of Directors of the Company (the “Board”), effective immediately. Ms. Floegel’s decision to resign did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
NEOGENOMICS, INC.
Date:August 8, 2025
By:
/s/ Alicia C. Olivo
Alicia C. Olivo
EVP, General Counsel & Business Development
and Corporate Secretary



FAQ

Who resigned from the NeoGenomics (NEO) board?

Elizabeth Floegel resigned from the Board of Directors, as disclosed in the filing.

When did Elizabeth Floegel’s resignation take effect?

The filing states the resignation was effective immediately on the date reported.

Was the resignation due to a disagreement with NeoGenomics (NEO)?

No. The filing explicitly states the resignation did not result from any disagreement with the Company on operations, policies or practices.

Did NeoGenomics (NEO) name a replacement director in the filing?

The filing does not mention any replacement or nominee to fill the vacated Board seat.

Who signed the report on behalf of NeoGenomics (NEO)?

The report was signed by Alicia C. Olivo, EVP, General Counsel & Business Development and Corporate Secretary, as shown in the filing.
Neogenomics Inc

NASDAQ:NEO

NEO Rankings

NEO Latest News

NEO Latest SEC Filings

NEO Stock Data

865.50M
127.51M
1.3%
100.56%
3.88%
Diagnostics & Research
Services-testing Laboratories
United States
FORT MYERS